CN111088207A - 一种在大肠杆菌中提高合成戊二酸产量的生物催化方法 - Google Patents
一种在大肠杆菌中提高合成戊二酸产量的生物催化方法 Download PDFInfo
- Publication number
- CN111088207A CN111088207A CN202010013983.8A CN202010013983A CN111088207A CN 111088207 A CN111088207 A CN 111088207A CN 202010013983 A CN202010013983 A CN 202010013983A CN 111088207 A CN111088207 A CN 111088207A
- Authority
- CN
- China
- Prior art keywords
- agtabcd
- glutaric acid
- coli
- escherichia coli
- yield
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 title claims abstract description 47
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 24
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 31
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000012258 culturing Methods 0.000 claims abstract description 18
- 239000004472 Lysine Substances 0.000 claims abstract description 16
- 235000019766 L-Lysine Nutrition 0.000 claims abstract description 15
- 229940073490 sodium glutamate Drugs 0.000 claims abstract description 9
- 239000004094 surface-active agent Substances 0.000 claims abstract description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 8
- 239000004220 glutamic acid Substances 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 8
- 108090000790 Enzymes Proteins 0.000 claims abstract description 7
- 102000004190 Enzymes Human genes 0.000 claims abstract description 7
- 239000013612 plasmid Substances 0.000 claims abstract description 7
- 238000006555 catalytic reaction Methods 0.000 claims abstract description 6
- 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 claims abstract description 5
- 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 claims abstract description 5
- 230000000593 degrading effect Effects 0.000 claims abstract description 4
- 230000003313 weakening effect Effects 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims description 11
- WIIZWVCIJKGZOK-IUCAKERBSA-N 2,2-dichloro-n-[(1s,2s)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide Chemical compound ClC(Cl)C(=O)N[C@@H](CO)[C@@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-IUCAKERBSA-N 0.000 claims description 10
- 229930027917 kanamycin Natural products 0.000 claims description 10
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 10
- 229960000318 kanamycin Drugs 0.000 claims description 10
- 229930182823 kanamycin A Natural products 0.000 claims description 10
- 230000002210 biocatalytic effect Effects 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 239000008055 phosphate buffer solution Substances 0.000 claims description 7
- 230000002238 attenuated effect Effects 0.000 claims description 6
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 5
- 101710088194 Dehydrogenase Proteins 0.000 claims description 4
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 claims description 3
- 108020004705 Codon Proteins 0.000 claims description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 241001640034 Heteropterys Species 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 239000013599 cloning vector Substances 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 238000007747 plating Methods 0.000 claims description 2
- 238000012795 verification Methods 0.000 claims description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 abstract description 9
- 239000000725 suspension Substances 0.000 abstract 2
- 238000003306 harvesting Methods 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 7
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 7
- 229960000723 ampicillin Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108091006151 Glutamate transporters Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 101100070615 Acidaminococcus fermentans (strain ATCC 25085 / DSM 20731 / CCUG 9996 / CIP 106432 / VR4) hgdH gene Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- -1 alkyl glutarates Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000013064 chemical raw material Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003546 flue gas Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZTOMUSMDRMJOTH-UHFFFAOYSA-N glutaronitrile Chemical compound N#CCCCC#N ZTOMUSMDRMJOTH-UHFFFAOYSA-N 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
- 229960003296 pitavastatin calcium Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920005906 polyester polyol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 229960004796 rosuvastatin calcium Drugs 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 101150026728 tesB gene Proteins 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/44—Polycarboxylic acids
- C12P7/50—Polycarboxylic acids having keto groups, e.g. 2-ketoglutaric acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/04—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a disulfide as acceptor (1.2.4)
- C12Y102/04002—Oxoglutarate dehydrogenase (succinyl-transferring) (1.2.4.2), i.e. alpha-ketoglutarat dehydrogenase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了一种在大肠杆菌中提高合成戊二酸产量的生物催化方法。该方法即在质粒pACYC‑gabTD上过表达agtABCD 谷氨酸转运基因得pACYC‑gabTD(agtABCD);减弱大肠杆菌上降解α‑酮戊二酸的关键酶系α‑酮戊二酸脱氢酶系的功能;重组菌株E.coliBL‑22AB和E.coli‑YDT(agtABCD)‑28LGOX1培养收菌后分别用pH7.0的PBS重悬并浓缩后加入催化体系中,加入0.5%TritonX‑100作为表面活性剂,再加入L‑赖氨酸和L‑谷氨酸钠催化反应生成戊二酸。本发明方法使得生产成本得到进一步降低,是一种产率高、利用谷氨酸循环催化生产戊二酸的方法。
Description
技术领域
本发明涉及戊二酸制备技术领域,具体涉及一种在大肠杆菌中提高合成戊二酸产量的生物催化方法。
背景技术
戊二酸,别名:胶酸,α,γ一丙烷二竣酸,1,3一丙二竣酸,分子式为C5H8O4,是一种重要的有机化工原料和中间体,在化学、建筑、医药、农业等方面具有广泛的应用。在塑料工业中,戊二酸及其戊二酸烷基酯类主要作为增塑剂的中间体,是聚氯乙烯、聚酯、聚酰胺以及聚氯乙烯的聚酯增塑剂的组成成分。在医药方面,戊二酸主要用于合成戊二酸酐,而戊二酸酐又可以作为很多药物的中间体,可用于合成新一代降血脂类药匹伐他汀和瑞舒伐他汀钙片。由于其良好的广谱杀菌能力,可以用来合成各种杀菌消毒洗液和医用药品等等。戊二酸也可合成液态聚酯,用于改良PET纤维的分子结构,从而改进PET纤维的染色性,提高上染率。利用戊二酸配制粘合剂可广泛粘接纺织品、金属等。此外,戊二酸或其酯也可用于聚酯多醇的合成、去垢剂的配制、含硫等烟道气的洗涤。
合成戊二酸的传统方法有回收法,化学合成法。回收法生产戊二酸主要依赖从己二酸的副产物中分离提纯,此法操作繁琐流程长,回收率低且不稳定。合成法主要有环戊酮液相氧化法、γ- 丁内酯法、二氢吡喃法和戊二腈法。合成法大多原料昂贵不易得,试剂毒性大污染环境,产品收率低,合成路线复杂等缺点。
Si Jae Park等人采用过表达了davAB和GabDT的重组E .coli WL3110菌株,在含有赖氨酸,葡萄糖和α-酮戊二酸的培养基里共同发酵生产了1 .7g/L戊二酸。此法发酵周期长且转化率低,且需要添加昂贵的α-酮戊二酸作为氨基受体,大大增加了生产成本。
Jia-Le Yu等人采用过表达了hgdH ,、gctAB、hgdABC、ter和tesB的重组E .coli菌株,以α-酮戊二酸为底物厌氧培养得到了3 .8mg/L戊二酸。此法反应体系复杂,原料昂贵且有副产物生成,戊二酸摩尔收率低。
目前为止,通过过表达谷氨酸转运基因、减弱α-酮戊二酸脱氢酶系以及加入表面活性剂的双细胞耦合后谷氨酸循环催化生产戊二酸的方法尚未见报道。
发明内容
针对现有技术的不足,本发明的目的在于提供一种在大肠杆菌中提高合成戊二酸产量的生物催化方法,该方法催化效果好,且中间产物少。
一种在大肠杆菌中提高合成戊二酸产量的生物催化方法,包括以下步骤:
步骤1,在实验室现有质粒pACYC-gabTD上过表达agtABCD 谷氨酸转运基因得pACYC-gabTD(agtABCD),所述agtABCD 谷氨酸转运基因来源于Pseudomonas aeruginosa ;
步骤2,减弱大肠杆菌上降解α-酮戊二酸的关键酶系α-酮戊二酸脱氢酶系的功能;
步骤3,培养重组菌株E .coliBL-22AB和E .coli-YDT(agtABCD)-28LGOX1,分别用pH7.0的PBS重悬并浓缩后,加入表面活性剂质量分数为0.5%TritonX-100,最后加入L-赖氨酸和L-谷氨酸钠催化反应生成戊二酸。
作为改进的是,步骤1中将agtABCD基因密码子优化后交由思普金生物科技有限公司合成于载体pACYC-gabTD的NcoI/EcoR I酶切位点之间,转入克隆载体Trans1-T1,经过LB平板初筛后,挑点进行菌落PCR验证后测序。
作为改进的是,步骤2中在大肠杆菌BL21(DE3)中通过利用Crispr-Cas9编辑技术减弱降解α-酮戊二酸的关键酶系α-酮戊二酸脱氢酶系的功能。
作为改进的是,步骤3中所述E .coli-YDT(agtABCD)-28LGOX1的构建方法如下:将pACYC-gabTD(agtABCD)和pET28a-LGOX共同导入减弱α-酮戊二酸脱氢酶系的 BL21(DE3)中,并涂布在含有35mg/L氯霉素抗性和50mg/L卡那霉素抗性的平板上,37℃过夜培养,得到重组菌株E .coli BL-YDT(agtABCD)-28LGOX1。
作为改进的是,所述将重组菌株E .coli-YDT( agtABCD )-28LGOX1与E.coliBL21-22AB的细胞OD比例关系为4:1。
作为改进的是,步骤3中所述L-赖氨酸和L-谷氨酸钠的添加的摩尔比为1:3。
有益效果:
与现有技术相比,本发明一种在大肠杆菌中提高合成戊二酸产量的生物催化方法的优势在于:
1、通过过表达谷氨酸转运基因 agtABCD ,提高了谷氨酸的利用效率,减少了对于底物的需求,节约了成本;
2、利用Crispr-Cas9技术减弱大肠杆菌自带的α-酮戊二酸支路基因,减少了α-酮戊二酸的降解,使得能够与谷氨酸循环,经济有效;
3、通过加入表面活性剂,提高了细胞间的传质速率,使得底物L-赖氨酸的消耗速率和产物戊二酸的合成速率都有所提高。
附图说明
图1为E .coli BL-22AB细胞OD600=5与E .coli-YDT(agtABCD)-28LGOX细胞OD600=5双细胞耦合催化生产戊二酸,L-赖氨酸为10g/L,L-谷氨酸钠为12g/L时对戊二酸的积累的影响;
图2为E .coli BL-22AB细胞OD600=5与E .coli-YDT(agtABCD)-28LGOX1细胞OD600=5减弱大肠杆菌α-酮戊二酸支路基因表达后,双细胞耦合催化生产戊二酸,L-赖氨酸为10g/L,L-谷氨酸钠为12 g/L时对戊二酸的积累的影响;
图3为E .coli BL-22AB细胞OD600=5与E .coli-YDT(agtABCD)-28LGOX1细胞OD600=5双细胞耦合催化生产戊二酸,L-赖氨酸为10g/L,L-谷氨酸钠为12 g/L时,添加0.5%表面活性剂TritonX-100对戊二酸的积累的影响。
具体实施方式
以下通过具体实施方式的描述对本发明作进一步说明,但这并非是对本发明的限制,本领域技术人员根据本发明的基本思想,可以做出各种修改或改进,但是只要不脱离本发明的基本思想,均在本发明的范围之内。
本发明中质粒pACYC-gabTD、pET28a-LGOX以及菌株E.coliBL21-22AB具体构建方法见本课题组已公开专利:一种双细胞耦合催化生产戊二酸的方法以及利用大肠杆菌表达DavA、DavB、GabD、GabT和LGOX产戊二酸的方法。
实施例1 过表达谷氨酸转运基因agtABCD
1.重组菌株E.coli BL-YDT(agtABCD)-28LGOX的构建
将agtABCD基因密码子优化后交由思普金生物科技有限公司合成于载体pACYC-gabTD的NcoI/EcoR I酶切位点之间,转入大肠杆菌Trans1-T1,PCR筛选阳性菌株Trans1-T1-pACYC-gabTD(agtABCD)并进行DNA测序,验证重组质粒构建正确。
将阳性菌株Trans1-T1-pACYC-gabTD(agtABCD)接种至5ml LB/Cmr液体培养基,所述LB/Cmr液体培养基组成为:蛋白胨10g/L、酵母粉5g/L、氯化钠5g/L,于37℃、200rpm 条件下振荡培养过夜。
24小时后按照天根质粒提试剂盒操作说明提取质粒pACYC-gabTD(agtABCD)。分别取2μL pACYC-gabTD(agtABCD)以及pET28a-LGOX共同导入 E .coli BL21(DE3)中,并涂布在含有35mg/L氯霉素抗性和50mg/L卡那霉素抗性的平板上,37℃过夜培养,得到重组菌株E.coli BL-YDT(agtABCD)-28LGOX。
2.双细胞耦合催化生产戊二酸
将重组菌株E .coli BL-22AB的单菌落接种到含有100mg/L氨苄青霉素抗性的5mlLB摇管里,37℃培养6-8h后,全部转接到含有100mg/L氨苄青霉素抗性的100ml摇瓶里,37℃培养至OD600=0 .3,加入1mmol的IPTG,20℃诱导12h,7000g离心5min,得到重组菌株E .coliBL-22AB的细胞;
挑取重组菌株E .coli BL-YDT(agtABCD)-28LGOX的单菌落接种到含有35mg/L氯霉素抗性和50mg/L卡那霉素抗性的5mlLB摇管里,37℃培养6-8h后,转接到含有35mg/L氯霉素抗性和50mg/L卡那霉素抗性的100ml摇瓶里,37℃分别培养至OD600为0.3,加入0 .5mmol的IPTG,20℃诱导12h,7000g离心5min,得到重组菌株E.coli BL-YDT(agtABCD)-28LGOX的细胞;将收集好的细胞用pH 7.0的PBS重悬并浓缩加入到催化体系中,加入底物L-赖氨酸和L-谷氨酸钠催化反应生成戊二酸。
其产戊二酸情况如图1所示,在L-赖氨酸为10g/L,L-谷氨酸钠为12 g/L时,过表达菌株戊二酸的积累明显高于原始菌株,较未优化前产量提高了2.5倍。
实施例2 减弱大肠杆菌α-酮戊二酸支路基因表达
1.重组菌株E .coli BL-YDT(agtABCD)-28LGOX1的构建
将pACYC-gabTD(agtABCD)和pET28a-LGOX共同导入减弱α-酮戊二酸脱氢酶系的 BL21(DE3)中,并涂布在含有35mg/L氯霉素抗性和50mg/L卡那霉素抗性的平板上,37℃过夜培养,得到重组菌株E .coli BL-YDT(agtABCD)-28LGOX1。
2.双细胞耦合催化生产戊二酸
将重组菌株E .coli BL-22AB的单菌落接种到含有100mg/L氨苄青霉素抗性的5mlLB摇管里,37℃培养6-8h后,全部转接到含有100mg/L氨苄青霉素抗性的100ml摇瓶里,37℃培养至OD600=0 .3,加入1mmol的IPTG,20℃诱导12h,7000g离心5min,得到重组菌株E .coliBL-22AB的细胞;
挑取重组菌株E .coli BL-YDT(agtABCD)-28LGOX1的单菌落接种到含有35mg/L氯霉素抗性和50mg/L卡那霉素抗性的5mlLB摇管里,37℃培养6-8h后,转接到含有35mg/L氯霉素抗性和50mg/L卡那霉素抗性的100ml摇瓶里,37℃分别培养至OD600为0 .3,加入0 .5mmol的IPTG,20℃诱导12h,7000g离心5min,得到重组菌株E .coli BL-YDT(agtABCD)-28LGOX1的细胞;将收集好的细胞用pH 7.0的PBS重悬并浓缩加入到催化体系中,加入底物L-赖氨酸和L-谷氨酸钠催化反应生成戊二酸。
其产戊二酸情况如图2所示,在L-赖氨酸为10g/L,L-谷氨酸钠为12 g/L时,减弱基因表达的菌株戊二酸的积累明显高于原始菌株,较未优化前产量提高了1.8倍。
实施例3添加表面活性剂双细胞耦合催化生产戊二酸
将重组菌株E .coli BL-22AB的单菌落接种到含有100mg/L氨苄青霉素抗性的5mlLB摇管里,37℃培养6-8h后,全部转接到含有100mg/L氨苄青霉素抗性的100ml摇瓶里,37℃培养至OD600=0 .3,加入1mmol的IPTG,20℃诱导12h,7000g离心5min,得到重组菌株E .coliBL-22AB的细胞;挑取重组菌株E .coli BL-YDT(agtABCD)-28LGOX1的单菌落接种到含有35mg/L氯霉素抗性和50mg/L卡那霉素抗性的5mlLB摇管里,37℃培养6-8h后,转接到含有35mg/L氯霉素抗性和50mg/L卡那霉素抗性的100ml摇瓶里,37℃分别培养至OD600为0 .3,加入0 .5mmol的IPTG,20℃诱导12h,7000g离心5min,得到重组菌株E .coli BL-YDT(agtABCD)-28LGOX1的细胞;将收集好的细胞用pH 7.0的PBS重悬并浓缩加入到催化体系中,加入0 .5%TritonX-100作为表面活性剂,加入底物L-赖氨酸和L-谷氨酸钠催化反应生成戊二酸。
其产戊二酸情况如图3所示,在L-赖氨酸为10g/L,L-谷氨酸钠为12 g/L时,加入表面活性剂后双细胞耦合产戊二酸较未优化前产量提高了4倍。
Claims (6)
1.一种在大肠杆菌中提高合成戊二酸产量的生物催化方法,其特征在于,包括以下步骤:
步骤1,在实验室已有质粒pACYC-gabTD上过表达agtABCD 谷氨酸转运基因得pACYC-gabTD(agtABCD),所述agtABCD 谷氨酸转运基因来源于Pseudomonas aeruginosa ;
步骤2,减弱大肠杆菌上降解α-酮戊二酸的关键酶系α-酮戊二酸脱氢酶系的功能;
步骤3,培养重组菌株E .coliBL-22AB和E .coli-YDT(agtABCD)-28LGOX1,分别用pH7.0的PBS重悬并浓缩后,加入表面活性剂质量分数为0.5%TritonX-100,最后加入L-赖氨酸和L-谷氨酸钠催化反应生成戊二酸。
2.根据权利要求1所述的一种在大肠杆菌中提高合成戊二酸产量的生物催化方法,其特征在于,步骤1中将agtABCD基因密码子优化后交由思普金生物科技有限公司合成于载体pACYC-gabTD的NcoI/EcoR I酶切位点之间,转入克隆载体Trans1-T1,经过LB平板初筛后,挑点进行菌落PCR验证后测序。
3.根据权利要求1所述的一种在大肠杆菌中提高合成戊二酸产量的生物催化方法,其特征在于,步骤2中在大肠杆菌BL21(DE3)中通过利用Crispr-Cas9编辑技术减弱降解α-酮戊二酸的关键酶系α-酮戊二酸脱氢酶系的功能。
4.根据权利要求1所述的一种在大肠杆菌中提高合成戊二酸产量的生物催化方法,其特征在于,步骤3中所述E .coli-YDT(agtABCD)-28LGOX1的构建方法如下:将pACYC-gabTD(agtABCD)和pET28a-LGOX共同导入减弱α-酮戊二酸脱氢酶系的 BL21(DE3)中,并涂布在含有35mg/L氯霉素抗性和50mg/L卡那霉素抗性的平板上,37℃过夜培养,得到重组菌株E.coli BL-YDT(agtABCD)-28LGOX1。
5.根据权利要求1所述的一种在大肠杆菌中提高合成戊二酸产量的生物催化方法,其特征在于,所述将重组菌株E .coli-YDT( agtABCD )-28LGOX1与E.coliBL21-22AB的细胞OD比例关系为4:1。
6.根据权利要求1所述的一种在大肠杆菌中提高合成戊二酸产量的生物催化方法,其特征在于,步骤3中所述L-赖氨酸和L-谷氨酸钠的添加的摩尔比为1:3。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010013983.8A CN111088207A (zh) | 2020-01-07 | 2020-01-07 | 一种在大肠杆菌中提高合成戊二酸产量的生物催化方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010013983.8A CN111088207A (zh) | 2020-01-07 | 2020-01-07 | 一种在大肠杆菌中提高合成戊二酸产量的生物催化方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111088207A true CN111088207A (zh) | 2020-05-01 |
Family
ID=70400422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010013983.8A Pending CN111088207A (zh) | 2020-01-07 | 2020-01-07 | 一种在大肠杆菌中提高合成戊二酸产量的生物催化方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111088207A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116813466A (zh) * | 2023-08-28 | 2023-09-29 | 江苏惠利生物科技有限公司 | 一种α-酮戊二酸的制备工艺 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102268469A (zh) * | 2010-06-04 | 2011-12-07 | 南京工业大学 | 一种环磷酸腺苷的制备方法 |
CN108949654A (zh) * | 2018-04-19 | 2018-12-07 | 江南大学 | 一种工程菌及其在生产α-酮戊二酸中的应用 |
CN108949657A (zh) * | 2018-04-19 | 2018-12-07 | 江南大学 | 一种工程菌及其在丹参素和α-酮戊二酸联产中的应用 |
CN109868297A (zh) * | 2019-03-19 | 2019-06-11 | 南京工业大学 | 利用大肠杆菌表达DavA、DavB、GabD、GabT和LGOX产戊二酸的方法 |
-
2020
- 2020-01-07 CN CN202010013983.8A patent/CN111088207A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102268469A (zh) * | 2010-06-04 | 2011-12-07 | 南京工业大学 | 一种环磷酸腺苷的制备方法 |
CN108949654A (zh) * | 2018-04-19 | 2018-12-07 | 江南大学 | 一种工程菌及其在生产α-酮戊二酸中的应用 |
CN108949657A (zh) * | 2018-04-19 | 2018-12-07 | 江南大学 | 一种工程菌及其在丹参素和α-酮戊二酸联产中的应用 |
CN109868297A (zh) * | 2019-03-19 | 2019-06-11 | 南京工业大学 | 利用大肠杆菌表达DavA、DavB、GabD、GabT和LGOX产戊二酸的方法 |
Non-Patent Citations (3)
Title |
---|
CHOU H T 等: "L-Lysine Decarboxylase and Cadaverine Gamma-Glutamylation Pathways in Pseudomonas Aeruginosa PAO1", 《BIOLOGY DISSERTATIONS》 * |
CHOU HT等: "Functional characterization of the agtABCD and agtSR operons for 4-aminobutyrate and 5-aminovalerate uptake and regulation in Pseudomonas aeruginosa PAO1", 《CURR MICROBIOL》 * |
LAGRANHA VL等: "Increased glutamate receptor and transporter expression in the cerebral cortex and striatum of gcdh-/- mice: possible implications for the neuropathology of glutaric acidemia type I", 《PLOS ONE》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116813466A (zh) * | 2023-08-28 | 2023-09-29 | 江苏惠利生物科技有限公司 | 一种α-酮戊二酸的制备工艺 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7923225B2 (en) | Method for the enzymatic production of 2-hydroxy-2-methyl carboxylic acids | |
US20160244790A1 (en) | Enzymatic amination | |
CN109136295B (zh) | 一种生物合成戊二酸的方法 | |
CN112831488B (zh) | 一种谷氨酸脱羧酶及γ-氨基丁酸高产菌株 | |
CN108866117B (zh) | 一种利用光合细菌合成3-羟基丙酸的方法及其相应重组细胞和应用 | |
CN111019982B (zh) | 一种利用羟基酸脱氢酶制备l-草铵膦的方法 | |
CN111088207A (zh) | 一种在大肠杆菌中提高合成戊二酸产量的生物催化方法 | |
CN117305206A (zh) | 一种生产d-对羟基苯甘氨酸的重组菌及其应用 | |
CN113355299A (zh) | 酮酸还原酶、基因、工程菌及在合成手性芳香2-羟酸中的应用 | |
CN115895989B (zh) | 一株高产丁二酸的大肠杆菌及其制备方法与应用 | |
CN113502305B (zh) | 一种利用重组酰亚胺酶合成(r)-异丁基戊二酸单酰胺的方法 | |
CN109593739A (zh) | 重组酮酸还原酶突变体、基因、工程菌及其应用 | |
CN110804602B (zh) | 一种L-天冬氨酸β-脱羧酶突变体及其应用 | |
WO2023092632A1 (zh) | 高效生产戊二酸的重组大肠杆菌及其构建方法与应用 | |
CN114891711B (zh) | 一种通过强化电子传递提高重组大肠杆菌催化合成胆绿素的方法 | |
CN113388627B (zh) | 还原酶lx05基因,含有该基因的基因工程菌及其应用 | |
CN115851684B (zh) | 一种腈水解酶及其在蛋氨酸合成中的应用 | |
CN114958703B (zh) | 一种利用油脂合成丁二酸的重组菌及其构建方法与应用 | |
CN113025546B (zh) | 一种多酶级联转化l-酪氨酸生产酪醇的方法 | |
CN115975967A (zh) | 乙醇酸氧化酶及其应用 | |
CN113308486A (zh) | 一种基因工程菌株生物催化生产l-苯甘氨酸的方法 | |
CN117210431A (zh) | 一种热稳定性转氨酶突变体及其工程菌与应用 | |
CN118222469A (zh) | 一种戊二酸生产菌株及其构建方法和应用 | |
CN118620880A (zh) | 一种酶组合物及其在制备l-正缬氨酸中的应用 | |
CN115058464A (zh) | 4-(甲基羟基磷酰基)-2-羰基丁酸制备精草铵膦的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200501 |